Lake Street lowered the firm’s price target on OptimizeRx (OPRX) to $20 from $24 and keeps a Buy rating on the shares. While “disappointed” with the lowered revenue outlook for 2026, the firm is “pleased to bump up our profit forecast,” adding that it believes the new $10M repurchase authorization will support shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $11 from $28 at B. Riley
- OptimizeRx price target lowered to $18 from $32 at Roth Capital
- OptimizeRx price target lowered to $17 from $21 at Stifel
- OptimizeRx price target lowered to $10 from $17 at Stephens
- OptimizeRx: Strong Q4 Execution, Temporary Headwinds, and Raised Profitability Guidance Support Buy Rating